Pharma Market Complaint Investigations & Mock Recalls: 21 CFR §211.198 Compliance & CAPA Root Cause

Health authorities require written procedures describing the handling of all written and oral complaints regarding a drug product. Inquiries into product quality defects (contamination, sub-potency, particulate matter, packaging defects) or adverse medical events must be logged contemporaneously and investigated thoroughly.

Failure to document and resolve complaints promptly is a frequent citation in FDA Warning Letters.

Regulatory authorities and cGMP standards mandate annual mock recall exercises to verify that a manufacturer can track and locate 100% of a distributed commercial batch within 2 to 4 hours: • Upstream Material Traceability: Instant backward tracing from finished product batch number to raw material API lots, primary packaging foils, and analytical testing certificates in Novaqis ERP and LIMS. • Downstream Distribution Traceability: Instant forward tracing to distributors, hospital consignees, and export shipments with quantity reconciliation (Distributed vs In-Transit vs Quarantine). • Mock Recall Scorecard: Automatic generation of regulatory distribution ledgers and percentage recovery reconciliation reports in under 15 minutes.

Novaqis QMS integrates complaint management with quality investigations: complaint samples are accessioned into Novaqis LIMS for reserve sample testing, deviations in manufacturing batch records are cross-checked in Novaqis BRM, and corrective actions are tracked through formal CAPA effectiveness verification.